Pembrolizumab

Drug Profile

Pembrolizumab

Alternative Names: Anti-PD-1 monoclonal antibody - Merck; Humanised monoclonal IgG4 antibody against PD-1 - Merck; Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Merck & Co; The Leukemia & Lymphoma Society
  • Developer Advaxis; Amgen; Big Ten Cancer Research Consortium; BioLineRx; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; DNAtrix; Eisai Co Ltd; Eli Lilly; Fox Chase Cancer Center; Genexine; Hoosier Cancer Research Network; ImmunoGen; Incyte Corporation; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Northwestern University; Plexxikon; Providence Health & Services; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; TG Therapeutics Inc; University of Alabama; University of Birmingham; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; PDCD 1 protein inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Head and neck cancer; Malignant melanoma; Non-small cell lung cancer
  • Registered Hodgkin's disease
  • Preregistration Urogenital cancer
  • Phase III Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Multiple myeloma; Oesophageal cancer; Renal cell carcinoma
  • Phase II Bladder cancer; Bone cancer; Brain metastases; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Inflammatory breast cancer; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thymoma; Thyroid cancer; Type 2 diabetes mellitus
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Haematological malignancies; Hepatocellular carcinoma
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 17 Apr 2017 Mayo clinic and National Cancer Institute plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, First-line therapy, Unresectable/Inoperable) in USA (NCT03106415)
  • 11 Apr 2017 Health Canada approves clinical trial application for EMD 640744 and Pembrolizumab in Ovarian cancer
  • 29 Mar 2017 Fox Chase Cancer Center, Celgene and Merck Sharp & Dohme initiate a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) and Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02963610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top